Bioventus Inc. (NYSE:BVS) Holdings Reduced by Hillsdale Investment Management Inc.

Hillsdale Investment Management Inc. cut its holdings in shares of Bioventus Inc. (NYSE:BVS) by 9.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 28,092 shares of the company’s stock after selling 3,100 shares during the period. Hillsdale Investment Management Inc.’s holdings in Bioventus were worth $295,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Plato Investment Management Ltd acquired a new position in Bioventus during the 4th quarter worth $38,000. Virtus Fund Advisers LLC bought a new stake in shares of Bioventus during the third quarter valued at about $42,000. Quest Partners LLC acquired a new stake in Bioventus in the third quarter worth about $51,000. Quarry LP bought a new position in Bioventus in the 3rd quarter valued at about $59,000. Finally, Quantbot Technologies LP acquired a new position in Bioventus during the 4th quarter valued at about $103,000. 62.94% of the stock is owned by institutional investors.

Bioventus Price Performance

Shares of NYSE BVS opened at $9.72 on Tuesday. Bioventus Inc. has a twelve month low of $3.90 and a twelve month high of $14.38. The company has a current ratio of 1.41, a quick ratio of 0.99 and a debt-to-equity ratio of 1.85. The firm has a 50-day moving average of $10.11 and a two-hundred day moving average of $11.01. The company has a market capitalization of $788.83 million, a price-to-earnings ratio of -15.93 and a beta of 0.86.

Analyst Ratings Changes

Several research analysts have recently issued reports on BVS shares. Canaccord Genuity Group reiterated a “buy” rating and issued a $15.00 price objective on shares of Bioventus in a report on Monday, March 17th. JPMorgan Chase & Co. raised Bioventus from an “underweight” rating to a “neutral” rating and increased their price target for the company from $12.00 to $13.00 in a research note on Tuesday, December 17th.

Insider Buying and Selling

In other Bioventus news, SVP Anthony D’adamio sold 4,380 shares of the company’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $10.19, for a total value of $44,632.20. Following the transaction, the senior vice president now owns 118,178 shares of the company’s stock, valued at approximately $1,204,233.82. This represents a 3.57 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Mark Leonard Singleton sold 6,498 shares of the firm’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $10.19, for a total value of $66,214.62. Following the sale, the chief financial officer now directly owns 118,817 shares of the company’s stock, valued at approximately $1,210,745.23. This represents a 5.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 40,682 shares of company stock worth $382,725 in the last ninety days. 32.90% of the stock is currently owned by corporate insiders.

Bioventus Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.